MARK2 and melanoma: The combined use of PAR1 and PAR2 antagonists my be beneficial in malignant melanoma since studies on melanoma cells have indicated that stimulation of cell motility by thrombin requires not only the activation of PAR1 but also the simultaneous activation of PAR2[137].